Search

Displaying results 1741 - 1750 of 5895 in total
  1. Drug

    Alteplase

    go.drugbank.com/drugs/DB00009
    ApprovedInvestigational

    [A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. … [L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots.

  2. Drug

    Artemether

    go.drugbank.com/drugs/DB06697
    ApprovedInvestigational

    Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

  3. Drug

    Zoledronic acid

    go.drugbank.com/drugs/DB00399
    ApprovedInvestigational

    Zoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid]. … [A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.

    Products: ACIDO ZOLEDRONICO DOC GENERICI, Zoledronic Acid Teva Generics
  4. Drug

    Sodium iodide

    go.drugbank.com/drugs/DB11119
    ApprovedInvestigational

    Radiolabelled compound, [DB09293], is used as a diagnostic tool to evaluate thyroid function and morphology.

  5. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. … [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary

  6. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma. … CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells.

  7. Drug

    Solifenacin

    go.drugbank.com/drugs/DB01591
    ApprovedInvestigational

    Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.

  8. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control[L42690].

  9. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    By improving the three-year survival rate from 55% to 84%,[L32288] and considering the lack of alternative therapies available, fosdenopterin appears poised to become a standard of therapy in the management … [A230088,A230593] In the past, management strategies for this disorder involved symptomatic and supportive treatment,[L32163] though efforts were made to develop a suitable exogenous replacement for the

  10. Drug

    Potassium perchlorate

    go.drugbank.com/drugs/DB09418
    ApprovedWithdrawn

    The therapeutic use of potassium perchlorate in thyroid disorders has been ceased due to a high risk for developing aplastic anemia and nephrotic syndrome [L2364].